ARE Stock Recent News

We prefer to buy and hold stocks with a significant margin of safety. Today, we're highlighting a global tech and e-commerce juggernaut, the leading life sciences REIT, and a major managed healthcare and insurance company. The stocks are priced 20% to 38% below our fair value estimates.

Alexandria Real Estate Equities is a best-in-class life sciences REIT trading at a deep discount, with fundamentals intact despite sector headwinds. The current nearly 7% dividend yield and a P/FFO at half its historical average create a compelling value opportunity for patient, long-term investors. Early signs of sector recovery—rising VC funding, employment, and leasing—suggest a bottoming and potential re-rating, especially if interest rates decline in 2026.

ARE offers a cream of the crop REIT investment case at a price that is characteristic to a speculative and deeply cyclical business. The 6.9% yield that we are getting is underpinned by top-tier fundamentals and actually a well-performing business. In the article, I discuss why the several areas where we see ARE struggling do not match the level of discount that is baked into the cake by the market.

The Big Beautiful Bill boosts defense, industrials, and manufacturing, but healthcare and some REITs face headwinds from Medicaid cuts and policy shifts. AI optimism and the new legislation are fueling a broad market rally, but I question if AI stocks are outpacing their earnings, signaling a potential bubble. The Magnificent 7 era is over; META, MSFT, NVDA, and AMZN are the new leaders, while AAPL, GOOG, and TSLA face unique challenges in the AI race.

REITs are positioned for accelerating earnings growth in 2026-2027, with management teams expressing increased optimism despite ongoing macro uncertainties. Key investment themes include AI-driven data centers, senior housing benefiting from demographic trends, and residential REITs capitalizing on the housing shortage. REITs offer resilient cash flows, potential dividend growth, and superior capital access, making them attractive relative to other asset classes in the current environment.

I love investing in dividend stocks. However, I have to be honest about the headwinds facing them right now. I share three reasons to avoid dividend stocks in H2 2025.

Alexandria Real Estate is a sector leader, with a strong client base, long-term leases, and predictable income, making it resilient, despite recent headwinds. The stock's recent 20% decline is driven by short-term revenue contraction and lowered FFO guidance, but I see this as a compelling buy opportunity. ARE boasts a best-in-class dividend profile, stable AFFO and EBITDA growth, and prudent debt management, supporting long-term value and financial flexibility.

Alexandria Real Estate Equities (ARE) owns a monopoly on top-tier biotech lab real estate, with long-term leases and blue-chip tenants in innovation hubs. Despite current oversupply and weak biotech financing, these headwinds are likely priced in, and new construction is slowing, setting up a recovery. AI-driven drug discovery is creating new demand for specialized lab space, and ARE's flexible, advanced facilities are uniquely positioned to benefit.

Despite some volatility earlier this year, the S&P 500 has rallied about 10% over the last 12 months. However, while most stocks are up in the past year, several have missed the market's current rally.

I discuss the keys to building a successful high-yield dividend growth portfolio. I share the key sectors to include. I also share some of the best funds and individual stocks for building a portfolio that yields over 7% and generates inflation-beating dividend growth.